US › Healthcare

Hoth Therapeutics Inc (HOTH)

US · Healthcare · Biotechnology

$0.82-7.93%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-2.7M
Profit YoY
+22.5%
EPS
$-0.16
EPS estimate
$-0.10

EPS came in at -0.16 against a street estimate of -0.10 — a miss of 60.0%.

Key statistics

Market cap
$26.0M
Forward P/E
0.0
P/B
4.30
Book value
$0.40
EPS (TTM)
$-0.80
52-week high
$2.45
52-week low
$0.49
50-day MA
$0.80
200-day MA
$1.11
Beta
0.58

Analyst view

Analysts rate Hoth Therapeutics Inc a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $5.00.

Shareholding

Insiders
2.89%
Institutions
4.11%

Largest institutional holders

FundStake
Geode Capital Management, LLC0.96%
Vanguard Group Inc0.96%
UBS Group AG0.71%
Vanguard Capital Management, LLC0.58%
Vanguard Fiduciary Trust Co0.38%
State Street Corp0.29%
Northern Trust Corp0.19%
Lido Advisors, LLC0.17%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Hoth Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.